Fresenius Nod In EU Adds To Crowded Adalimumab Market
Executive Summary
Fresenius Kabi has become the latest firm to receive a nod for a European biosimilar rival to Humira, adding to an already crowded biosimilar adalimumab market.
You may also be interested in...
Fresenius Kabi Acquires Ivenix For $240M To Expand Presence In Infusion Pump Market
Fresenius Kabi will pay up to $240m for Massachusetts-based Invenix to expand its infusion pump portfolio. Simultaneously, the company also made a major move to bolster its biosimilars business by acquiring a majority stake in mAbxience.
Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars
Fresenius Kabi has made a major move to bolster its biosimilars business by acquiring a majority 55% stake in mAbxience, with the purchase price comprising €495m upfront as well as subsequent milestone payments. The deal offers Fresenius not only enhanced biosimilars capabilities but also access to the expanding biologics CDMO market.
Fresenius Kabi Files EU Pegfilgrastim
Fresenius Kabi’s biosimilar pegfilgrastim rival to Neulasta has been accepted for review by the European Medicines Agency. The firm believes the “milestone” application will pave the way for a 2021 launch.